Biodegradable cannabidiol: a potential nanotherapeutic for neuropathic pain
Open Access
- 24 July 2024
- journal article
- research article
- Published by Walter de Gruyter GmbH in NeuroImmune Pharmacology and Therapeutics
- Vol. 3 (3-4) , 221-236
Abstract
Cannabidiol (CBD) is a promising pharmaceutical agent to treat pain, inflammation, and seizures without the psychoactive effects of delta-9-tetrahydrocannabinol (THC). While CBD is highly lipophilic and can cross the blood-brain barrier (BBB), its bioavailability is limited and clearance is quick, limiting its effectiveness in the brain. To improve its effectiveness, we developed a unique nanoformulation consisting of CBD encapsulated within the biodegradable and biocompatible polymer, methoxy polyethylene glycol-poly(lactic-co-glycolic acid) (mPEG-PLGA). mPEG-PLGA-CBD nanoparticles exhibited negligible cytotoxicity over a range of concentrations in CCK-8 assays performed in human astrocytes and brain microvascular endothelial cells. Furthermore, in an in-vitro BBB model, they exhibited rapid BBB permeability without harming BBB integrity. An in vivo Chronic Constriction Injury animal pain model was employed to study the efficacy of mPEG-PLGA-CBD in doses 1, 3 and 10 mg/kg, and it was found that 45–55 nm CBD nanoparticles with an encapsulation efficiency of 65 % can cross the BBB. Additionally, 3 and 10 mg/kg mPEG-PLGA-CBD nanoformulation provided prolonged analgesia in rats on day 2 and -4 post-injection, which we propose is attributed to the sustained and controlled release of CBD. Future studies are required to understand the pharmacokinetics of this nanoformulation.Keywords
Funding Information
- National Institute of Drug Abuse (Grant # 5R01DA047410-02)
- University at Buffalo, Center for Cannabis and Cannabinoid Research (Unassigned)
This publication has 56 references indexed in Scilit:
- Cannabidiol alleviates neuroinflammation and attenuates neuropathic pain via targeting FKBP5Brain, Behavior, and Immunity, 2023
- Transcellular Model for Neutral and Charged Nanoparticles Across an In Vitro Blood–Brain BarrierCardiovascular Engineering and Technology, 2020
- Cannabinoids: Potential Role in Inflammatory and Neoplastic Skin DiseasesAmerican Journal of Clinical Dermatology, 2018
- Drug Delivery to the Brain across the Blood–Brain Barrier Using NanomaterialsSmall, 2017
- GPR3 and GPR6, novel molecular targets for cannabidiolBiochemical and Biophysical Research Communications, 2017
- Polymeric nanoparticles for drug delivery to the central nervous systemAdvanced Drug Delivery Reviews, 2012
- The collection and processing of human brain tissue for researchCell and Tissue Banking, 2008
- Human Cannabinoid PharmacokineticsChemistry & Biodiversity, 2007
- Agonistic Properties of Cannabidiol at 5-HT1a ReceptorsNeurochemical Research, 2005
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodMethods, 2001